Table 2 Comorbidities of FASE-CPHG severe asthma clusters
Cluster 1 Early onset atopic (N = 690) | Cluster 2 Obese (N = 153) | Cluster 3 Late-onset (N = 299) | Cluster 4 Eosinophilic (N = 143) | Cluster 5 Aspirin-sensitivity (N = 139) | Patients N = 1424 | p | ||
|---|---|---|---|---|---|---|---|---|
Allergenic sensitization, n = 1158 | SPT positivity | 547 (79.3%) | 81 (52.9%) | 33 (11%) | 67 (46.9%) | 83 (59.7%) | 811 (70%) | < 0.0001 |
Aspirin sensitivity | Yes | 1 (0.1%) | 12 (7.8%) | 0 (0%) | 1 (0.7%) | 139 (100%) | 153 (10.7%) | < 0.0001 |
Nasal polyposis | Yes | 12 (1.7%) | 21 (13.7%) | 5 (1.7%) | 143 (100%) | 77 (55.4%) | 258 (18.1%) | < 0.0001 |
Allergic rhinitis | Yes | 323 (46.8%) | 69 (45.1%) | 96 (32.1%) | 80 (55.9%) | 74 (53.2%) | 642 (45.21%) | < 0.0001 |
Rhinosinusitis | Yes | 137 (19.9%) | 33 (21.6%) | 55 (18.4%) | 65 (45.5%) | 62 (44.6%) | 352 (24.7%) | < 0.0001 |
Obstructive apnea syndrome | Yes | 0 (0%) | 153 (100%) | 1 (0.3%) | 1 (0.7%) | 1 (0.7%) | 156 (11%) | < 0.0001 |
Reflux history | Yes | 231 (33.5%) | 75 (49%) | 129 (43.1%) | 50 (35%) | 70 (50.4%) | 555 (39%) | < 0.0001 |
Hypertension | Yes | 119 (17.2%) | 83 (54.2%) | 102 (34.1%) | 20 (14%) | 37 (26.6%) | 361 (25.4%) | < 0.0001 |
Smoking history | Active smoker | 108 (15.7%) | 8 (5.2%) | 32 (10.7%) | 7 (4.9%) | 11 (7.9%) | 166 (11.7%) | < 0.0001 |
Ex-smoker | 176 (25.5%) | 61 (39.9%) | 85 (28.4%) | 49 (34.3%) | 40 (28.8%) | 411 (28.9%) | ||
No-smoker | 406 (58.8%) | 84 (54.9%) | 182 (60.9%) | 87 (60.8%) | 88 (63.3%) | 847 (59.5%) | ||
Blood eosinophil count | < 300 | 331 (48%) | 66 (43.1%) | 150 (50.2%) | 36 (25.2%) | 63 (45.3%) | 646 (45.4%) | < 0.0001 |
[300–500] | 176 (25.5%) | 46 (30.1%) | 63 (21.1%) | 33 (23.1%) | 28 (20.1%) | 346 (24.3%) | ||
≥ 500 | 183 (26.5%) | 41 (26.8%) | 86 (28.8%) | 74 (51.7%) | 48 (34.5%) | 432 (30.3%) |